Research Article| Volume 153, ISSUE 2, P326-334, May 2019

Download started.


Retrospective study of a 16 year cohort of BRCA1 and BRCA2 carriers presenting for RRSO: Prevalence of invasive and in-situ carcinoma, with follow-up


      • The majority of high grade serous carcinoma in our cohort were of tubal origin.
      • High grade serous carcinoma was more common in BRCA1/2 carriers undergoing RRSO after the recommended age.
      • Isolated STIC can give rise to peritoneal serous carcinoma >7 years post-RRSO.



      Carriers of BRCA1 and BRCA2 mutations are at increased risk of high grade serous carcinoma and are therefore offered risk-reducing salpingo-oophorectomy (RRSO) by 40–45 years. Most of these carcinomas are believed to arise in the fallopian tube from serous tubal intraepithelial carcinoma (STIC). We conducted a retrospective study on the prevalence of high grade serous carcinoma and STIC in BRCA1/2 carriers presenting for RRSO, and their follow-up.


      Consecutive BRCA1/2 carriers presenting for an RRSO at Erasmus MC (2000–2016) were studied. SEE-FIM pathology protocol was followed from 2010 onwards. For the cases with carcinoma and/or STIC, the histology was reviewed and immunohistochemistry (p53 & MIB-1) was performed. Next Generation Targeted Sequencing (NGTS) for TP53 mutation was used to establish clonality in 2 cases.


      Of the 527 included patients, 68% were BRCA1, 31.6% were BRCA2, and 0.4% carried both mutations. The prevalence of high grade serous carcinoma was 2.3% (12/527); 59% of these were of tubal origin. High grade serous carcinoma was more common in patients operated on after the recommended age (p = 0.03). Isolated STIC was present in 0.8% (4/527). Two BRCA1 carriers with isolated STIC at RRSO developed peritoneal serous carcinoma >7 years later. Identical TP53 mutations in the peritoneal serous carcinoma and the preceding STIC established their clonal origin.


      High grade serous carcinoma is more common in BRCA1/2 carriers presenting for RRSO after the recommended age, and is more often of tubal origin. Longer follow up of patients with STIC at RRSO should be considered.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Gynecologic Oncology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


      1. L.A. Torre, F. Bray, R.L. Siegel, et al. Global cancer statistics 2012. CA Cancer J. Clin.. 65 (2015) 87–108. doi:

      2. K.B. Kuchenbaecker, J.L. Hopper, D.R. Barnes, et al. Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers. JAMA 317 (2017) 2402–2416. doi:

        • National Comprehensive Cancer Network
        Genetic/Familial High-Risk Assessment: Breast and Ovarian. NCNN Clinical Practice Guidelines in Oncology V12013.
        NCCN, Fort Washington (PA)2013
      3. . S.M. Domchek, T.M. Friebel, C.F. Singer, et al. Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA. 304 (2010) 967–975.

      4. J.M. Piek, P.J. van Diest, R.P. Zweemer, et al. Dysplastic changes in prophylactically removed fallopian tubes of women predisposed to developing ovarian cancer. J. Pathol. 195 (2001) 451–456.

      5. F. Medeiros, M.G. Muto, Y. Lee, et al. The tubal fimbria is a preferred site for early adenocarcinoma in women with familial ovarian cancer syndrome. Am. J. Surg. Pathol. 30 (2006) 230–236.

      6. . S.L. Wethington, K.J. Park, R.A. Soslow, et al. Clinical outcome of isolated serous tubal intraepithelial neoplasia (STIC). Int. J. Gynecol. Cancer 23 (2013) 1603–1611. doi:

      7. C.P. Crum, R. Drapkin, A. Miron, et al. The distal fallopian tube: a new model for pelvic serous carcinogenesis. Curr Opin Obstet Gynecol. 19 (2007) 3–9.

      8. J.C. Morrison, L.Z. Blanco, R. Vang, et al. Incidental serous tubal intraepithelial carcinoma and early invasive serous carcinoma in the nonprophylactic setting: analysis of a case series. Am. J. Surg. Pathol.. 39 (2015) 442–453. doi:

      9. D.R. Nebgen, J. Hurteau, L.L. Holman, et al. Bilateral salpingectomy with delayed oophorectomy for ovarian cancer risk reduction: a pilot study in women with BRCA1/2 mutations. Gynecol. Oncol. 150 (2018) 79–84. doi:

      10. . M.G Harmsen, M. Arts-de Jong M, N. Hoogerbrugge, et al. Early salpingectomy (TUbectomy) with delayed oophorectomy to improve quality of life as alternative for risk-reducing salpingo-oophorectomy in BRCA1/2 mutation carriers (TUBAstudy): a prospective non-randomised multicentre study. BMC Cancer. (2015)15:593. doi:

      11. . E. Leblanc E, F. Narducci, I. Farre, et al. Radical fimbriectomy: a reasonable temporary risk-reducing surgery for selected women with a germ line mutation of BRCA 1 or 2 genes? Rationale and preliminary development. Gynecol. Oncol. 121 (2011) 472–6. doi:

      12. Preventing ovarian Cancer through early excision of tubes and late ovarian removal (PROTECTOR) study, UK.
        Date: 2019
        Date accessed: February 11, 2019
      13. Women choosing surgical prevention (WISP) study.
      14. Oncoline (richtlijnen oncologische zorg).
      15. . METC Code Non-WMO Research. Central committee on research involving human subjects; [19th of March 2016]; Available from: Last accessed February, 2019.

      16. Y. Lee, F. Medeiros, D. Kindelberger, et al. Advances in the recognition of tubal intraepithelial carcinoma: applications to cancer screening and the pathogenesis of ovarian cancer. Adv. Anat. Pathol.. 13 (2006) 1–7.

      17. . N. Singh, C.B. Gilks, L. Hirschowitz, et al. Primary site assignment in tubo-ovarian high-grade serous carcinoma: consensus statement on unifying practice worldwide. Gynecol. Oncol. 141 (2016) 196–198. doi:

      18. . H.J. Dubbink, P.N. Atmodimedjo, R. van Marion, et al. Diagnostic detection of allelic losses and imbalances by next-generation sequencing 1p/19q co-deletion analysis of gliomas. J Mol Diagn. 18 (2016) 775–786. doi:

      19. M.G. Harmsen, J.M.J. Piek, J. Bulten,et al. Peritoneal carcinomatosis after risk-reducing surgery in BRCA1/2 mutation carriers. Cancer. 124 (2018) 952–959. doi:

      20. N.M.A. Van der Hoeven, K. Van Wijk, S.E. Bonfrer, et al. Outcome and prognostic impact of surgical staging in serous tubal intraepithelial carcinoma: a cohort study and systematic review. Clin Oncol (R Coll Radiol). 30 (2018) 463–471. doi:

        • Lee Y.J.
        • Lee S.W.
        • Kim K.R.
        • et al.
        Pathologic findings at risk-reducing salpingo-oophorectomy (RRSO) in germline BRCA mutation carriers with breast cancer: significance of bilateral RRSO at the optimal age in germline BRCA mutation carriers.
        J. Gynecol. Oncol. 2017; 28e3
      21. C. Garcia, J. Wendt, L. Lyon, et al. Risk management options elected by women after testing positive for a BRCA mutation. Gynecol. Oncol. 132 (2014) 428–433. doi:

      22. . J.R. Connor, E. Meserve, E. Pizer, et al. Outcome of unexpected adnexal neoplasia discovered during risk reduction salpingo-oophorectomy in women with germ-line BRCA1 or BRCA2 mutations. Gynecol. Oncol.. 132 (2014) 280–286. doi:

      23. R. Manchanda, A. Abdelraheim, M. Johnson, et al. Outcome of risk-reducing salpingo-oophorectomy in BRCA carriers and women of unknown mutation status. BJOG 118 (2011) 814–824. doi:

      24. . A. Finch A, M. Beiner, J. Lubinski, et al. Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 mutation. JAMA. 296 (2006) 185–192.

      25. J.D. Lamb, R.L. Garcia, B.A. Goff, et al. Predictors of occult neoplasia in women undergoing risk-reducing salpingo-oophorectomy. Am. J. Obstet. Gynecol. 194 (2006) 1702–1709.

      26. W. Reitsma, G.H. de Bock, J.C. Oosterwijk, et al. Support of the fallopian tube hypothesis; in a prospective series of risk-reducing salpingo-oophorectomy specimens. Eur. J. Cancer. 49 (2013) 132–141. doi:

        • Powell C.B.
        Risk reducing salpingo-oophorectomy for BRCA mutation carriers: twenty years later.
        Gynecol. Oncol. 2014; 132: 261-263
      27. . J.R. Connor, E. Meserve, E. Pizer, J. Garber, M. Roh, N. Urban et al. Outcome of unexpected adnexal neoplasia discovered during risk reduction salpingooophorectomy in women with germ-line BRCA1 or BRCA2 mutations. Gynecol. Oncol. 2 (2014) 280–6.

      28. . M.J. Mingels, T. Roelofsen, J.A. van der Laak, J.A. de Hullu JA, M.A. van Ham, L.F. Massuger, et al. Tubal epithelial lesions in salpingo-oophorectomy specimens of BRCA-mutation carriers and controls. Gynecol. Oncol. 127 (2012) 88–93.

      29. M. Zakhour, Y. Danovitch, J. Lester, B.J. Rimel, C.S. Walsh, A.J. Li, et al. Occult and subsequent cancer incidence following risk-reducing surgery in BRCA mutation carriers. Gynecol. Oncol. 143 (2016) 231–235.

        • Gaba F.
        • Piek J.
        • Menon U.
        • Manchanda R.
        Risk reducing early salpingectomy and delayed oophorectomy as a two staged alternative for primary prevention of ovarian cancer in increased risk women: a commentary.
        BJOG. 2019; (Epub ahead of print)
      30. M.G. Patrono, C. Corzo, M. Iniesta, et al. Management of preinvasive lesions. Clin. Obstet. Gynecol.. 60 (2017) 771–779. doi:

        • Chay W.Y.
        • Horlings H.M.
        • Tinker A.V.
        • Gelmon K.A.
        • Blake Gills C.
        Low grade serous carcinoma of the peritoneum in a BRCA1 carrier previously diagnosed with a “low-grade serous tubal intra-epithelial carcinoma” (STIC) on risk reducing surgery.
        Gynecologic Oncology Reports. 2015; 12: 72-74
        • Meserve E.E.
        • Brouwer J.
        • Crum C.P.
        Serous tubal intraepithelial neoplasia: the concept and its application.
        Mod. Pathol. 2017; 30: 710-721
      31. T.R. Soong, B.E. Howitt, A. Miron, N.S. Horowitz, F. Campbell, C.M. Feltmate et al. Evidence for lineage continuity between early serous proliferations (ESPs) in the fallopian tube and disseminated high-grade serous carcinomas. J. Pathol. 246 (2018) 344–351.

      32. S. Intidhar Labidi-Galy, E. Papp, D. Hallberg, N. Niknafs, V. Adleff, M. Noe, R. Bhattacharya et al. High grade serous ovarian carcinomas originate in the fallopian tube. Nat. Commun. 23 (2017):1093.

      33. K. Suda, H. Nakaoka, C. Hata, N. Yahata, M. Isobe, H. Kameyama et al. Concurrent isolated retroperitoneal HGSC and STIC defined by somatic mutation analysis: a case report. Diagn. Pathol. (2019) 14:17.